FGF23 and COVID-19: This multicenter observational study showed that patients with end-stage renal disease in chronic hemodialysis who presented high baseline plasma levels of FGF23 had a higher rate of SARS-CoV-2 infection and severe COVID-19, including hospitalizations and deaths.